Regulators beyond the FDA
Life sciences regulation does not end with product approval. Coverage and payment decisions by CMS and private plans determine whether a product can be reimbursed, and federal drug pricing programs impose reporting and rebate obligations on manufacturers whose products are covered by Medicaid and Medicare. Products with potential for abuse are scheduled and controlled by the DEA, which registers manufacturers and distributors. Interactions with prescribers and patients are governed by federal fraud and abuse laws enforced by the HHS Office of Inspector General and the Department of Justice. States add licensing for wholesale distribution and, in some cases, price transparency or marketing disclosure rules.
Rules that keep moving
Much of this field is shaped by guidance documents, agency practice, and enforcement priorities rather than by statute alone, and those can shift quickly. Drug pricing provisions, the oversight of laboratory-developed tests, and the treatment of compounded products have all been subject to change or litigation in recent years. As a result, a compliance plan written not long ago may rest on assumptions that no longer hold. Assign someone to watch for changes that affect your products and to flag them for review. When a rule is being challenged in court, the practical question is how to operate while its status is unsettled.
Mapping your obligations
We start with the product, its regulatory status, and how it reaches patients, from manufacturing through distribution to the prescriber and the payer. That map shows which agencies have a stake and where their requirements overlap. We then look at existing policies on promotion, pricing, and interactions with health care professionals to see whether they match the company's commercial plans. You get a prioritized list of obligations tied to the business plan rather than a survey of every possible rule.
